Our Piplines
1: DLL3: Delta-like ligand 3 (DLL3) is an appealing target for radioligand therapy (RLT) and theranostics due to its significant overexpression on cell surface of aggressive cancers like small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC), while showing minimal presence in healthy adult tissues. We have currently developed a radioligand with a low nM Kd.
2: GRPR: Gastrin-Releasing Peptide Receptor (GRPR)-targeted radioligand therapy (RLT) is an innovative, precision-focused cancer treatment. This approach involves attaching radioactive payloads to specific peptides, allowing for targeted radiation delivery to solid tumors that overexpress GRPR, such as those found in prostate, breast, and lung cancers, while protecting healthy surrounding tissue. Our compounds have demonstrated promising results in in vivo radio imaging.
3: FAP: In contrast to conventional therapies that directly target cancer cells, FAP-directed radioligands FAP-expressing cancer-associated fibroblasts (CAFs). Theseblasts are found in nearly all epithelial cancers but are typically absent in healthy tissues, offering a clear distinction for both imaging and treatment. We have made significant advancements with this target.
As a leader in radioligand therapy, we are passionate about pushing the boundaries of cancer treatment. Our dedicated team is focused on developing cutting-edge solutions to address the unmet needs of cancer patients. We aim to provide a detailed understanding of our research, development initiatives, and the impact we are striving to make in the field of cancer therapy. At Ymitter Therapeutics, we are committed to transparency, innovation, and excellence. Join us in our mission to transform the landscape of cancer treatment.
